<li>alosetron<p>esomeprazole will decrease the level or effect of alosetron by  increasing metabolism. Minor/Significance Unknown.</p></li><li>alprazolam<p>esomeprazole increases levels of alprazolam by decreasing metabolism. Minor/Significance Unknown.</p></li><li>ambrisentan<p>esomeprazole will increase the level or effect of ambrisentan by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>bismuth subsalicylate<p>esomeprazole increases levels of bismuth subsalicylate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>blessed thistle<p>blessed thistle decreases effects of esomeprazole by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.</p></li><li>bosentan<p>esomeprazole will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>chlordiazepoxide<p>esomeprazole will increase the level or effect of chlordiazepoxide by  decreasing metabolism. Minor/Significance Unknown.</p></li><li>clomipramine<p>esomeprazole will increase the level or effect of clomipramine by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>clonazepam<p>esomeprazole will increase the level or effect of clonazepam by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>cyanocobalamin<p>esomeprazole decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>cyclosporine<p>cyclosporine, esomeprazole. Other (see comment). Minor/Significance Unknown. 
Comment: Effectiveness of proton pump inhibitors may be decreased theoretically if administered with other antisecretory agents.</p></li><li>darifenacin<p>darifenacin will decrease the level or effect of esomeprazole by  Other (see comment). Minor/Significance Unknown. Effectiveness of proton pump inhibitors may be decreased theoretically if administered with other antisecretory agents</p></li><li>devil's claw<p>devil's claw decreases effects of esomeprazole by pharmacodynamic antagonism. Minor/Significance Unknown.</p></li><li>dexamethasone<p>dexamethasone will decrease the level or effect of esomeprazole by  increasing metabolism. Minor/Significance Unknown.</p></li><li>diazepam<p>esomeprazole will increase the level or effect of diazepam by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of esomeprazole by  decreasing metabolism. Minor/Significance Unknown.</p></li><li>efavirenz<p>efavirenz will increase the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df, esomeprazole. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Based on drug interaction studies conducted with the components of Stribild, no clinically significant drug interactions have been either observed or are expected when coadministered with PPIs.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate increases levels of esomeprazole by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown. Monitor for GI symptoms; net increased or decreased effect on PPI action unclear due to opposing CYP450 actions.<span><br><br></span>eslicarbazepine acetate decreases levels of esomeprazole by increasing metabolism. Minor/Significance Unknown. Monitor for GI symptoms; net increased or decreased effect on PPI action unclear due to opposing CYP450 actions.</p></li><li>estazolam<p>esomeprazole will increase the level or effect of estazolam by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>ferric carboxymaltose<p>esomeprazole will decrease the level or effect of ferric carboxymaltose by  increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>fluoxetine<p>fluoxetine will increase the level or effect of esomeprazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>flurazepam<p>esomeprazole increases levels of flurazepam by decreasing metabolism. Minor/Significance Unknown.</p></li><li>fluvastatin<p>esomeprazole will increase the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>levothyroxine<p>esomeprazole decreases levels of levothyroxine by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>liothyronine<p>esomeprazole decreases levels of liothyronine by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>liotrix<p>esomeprazole decreases levels of liotrix by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>lisdexamfetamine<p>esomeprazole, lisdexamfetamine. Other (see comment). Minor/Significance Unknown. 
Comment: Reduced gastric acidity caused by proton pump inhibitors decreases time to Tmax for amphetamine and dextroamphetamine. AUC was unaffected. .</p></li><li>lorazepam<p>esomeprazole increases levels of lorazepam by decreasing metabolism. Minor/Significance Unknown.</p></li><li>methamphetamine<p>esomeprazole decreases levels of methamphetamine by Other (see comment). Minor/Significance Unknown. 
Comment: Time to maximum concentration (Tmax) of amphetamine is decreased compared to when administered alone; monitor patients for changes in clinical effect and adjust therapy based on clinical response.</p></li><li>midazolam<p>esomeprazole increases levels of midazolam by decreasing metabolism. Minor/Significance Unknown.</p></li><li>phytoestrogens<p>esomeprazole decreases levels of phytoestrogens by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>theophylline<p>esomeprazole increases toxicity of theophylline by Other (see comment). Minor/Significance Unknown. 
Comment: Prolonged use of proton pump inhibitors can cause hypochlorhydria, which in turn causes peristalsis in small intestine to increase and peristalsis in the proximal colon to decrease; monitor for toxicity.</p></li><li>thyroid desiccated<p>esomeprazole decreases levels of thyroid desiccated by increasing gastric pH. Applies only to oral form of both agents. Minor/Significance Unknown. Conflicting evidence regarding this interaction exists.</p></li><li>triazolam<p>esomeprazole increases levels of triazolam by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>voriconazole<p>esomeprazole will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li><li>warfarin<p>esomeprazole will increase the level or effect of warfarin by  affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown.</p></li>